title: Comparison of p53 and CD44 variant 6 expression between paired primary and recurrent ovarian cancer: an immunohistochemical analysis.
abstract: Progression of malignant potential in ovarian cancer was investigated by comparing recurrent tumor with their primary tumor counterparts in terms of p53 and CD44 variant 6 (CD44v6) expression. Forty-three paired primary and recurrent tumors were immunohistochemically evaluated for expression of p53 and CD44v6. A paired analysis revealed that p53 and CD44v6 expression were significantly greater in recurrent tumors than those in the primary counterparts with statistical significance, respectively (P=0.0055 and 0.0071; Wilcoxon signed-rank test). No relationship between these two proteins was found. These results suggested that recurrent ovarian cancer may possibly express a stronger malignant potential in comparison to the primary tumor.
authors.affiliation: Department of Gynecology and Obstetrics, Faculty of Medicine, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kamura
authors.forename: K
authors.initials: K
authors.lastname: Sakai
authors.forename: T
authors.initials: T
authors.lastname: Kaku
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Mitsumoto
authors.forename: M
authors.initials: M
authors.lastname: Tsuneyoshi
authors.forename: H
authors.initials: H
authors.lastname: Nakano
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D002288:Adenocarcinoma, Mucinous / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018269:Carcinoma, Endometrioid / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018283:Cystadenocarcinoma, Papillary / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D018450:Disease Progression; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D016158:Genes, p53; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000032:analysis*; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: C112697:CD44v6 antigen; D006023:Glycoproteins; D018960:Hyaluronan Receptors; D009363:Neoplasm Proteins; D016159:Tumor Suppressor Protein p53; D015251:Epirubicin; D003520:Cyclophosphamide; D002945:Cisplatin